Cannabis use among recently treated cancer patients: perceptions and experiences

Salz, Talya; Meza, Akriti Mishra; Chino, Fumiko; Mao, Jun J.; Raghunathan, Nirupa J.; Jinna, Sankeerth; Brens, Jessica; Furberg, Helena; Korenstein, Deborah

doi:10.1007/s00520-023-07994-y

Cited by 8 publications

(2 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinicians are advised to exercise caution and thoroughly evaluate the potential risks of harm and adverse events before recommending cannabis-based treatments to patients [27,29,30]. However, even with these recommendations, pain continues to be one of the most common reasons that cancer patients take cannabis-based medicines for [31,32].…”

Section: Cancer-related Painmentioning

confidence: 99%

“…Studies have generally shown that cannabis-based medicines are more effective than placebos and similar to prochlorperazine. Adverse effects commonly reported in these studies include sedation, loss of emotional and/or physical control, nervousness, rebound nausea, somnolence, and depersonalization [24,[26][27][28][29][30][31][32][33][34]. In several studies, patients withdrew, or the study was discontinued because of adverse effects [43][44][45][46][47][48].…”

Section: Chemotherapy-induced Nausea and Vomitingmentioning

confidence: 99%

See 1 more Smart Citation

Review of the Use of Medicinal Cannabis Products in Palliative Care

Troyer,

Tanco

2024

Cancers

View full text Add to dashboard Cite

In this review, we discuss the potential role of cannabis and cannabinoids in the management of cancer-related symptoms. There is limited evidence demonstrating the effectiveness of cannabis-based products in treating cancer-related pain and gastrointestinal symptoms such as nausea, vomiting, and loss of appetite. Regarding the role of cannabis-based products in the treatment of insomnia and mood disorders, most studies looked at these symptoms as secondary outcomes with mixed results. Cannabis-based products have adverse effects, ranging from neuropsychiatric to systemic effects to potential drug interactions.

show abstract

Section: Cancer-related Painmentioning

confidence: 99%

Section: Chemotherapy-induced Nausea and Vomitingmentioning

confidence: 99%

Review of the Use of Medicinal Cannabis Products in Palliative Care

Troyer,

Tanco

2024

Cancers

View full text Add to dashboard Cite

show abstract

Cannabis Use Among Cancer Patients During Active Treatment: Findings From a Study at an NCI‐Designated Cancer Center

Baral,

Diggs,

Marrakchi El Fellah

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

ObjectiveThis study aims to describe patterns, sources, and reasons for cannabis use among cancer patients during active treatment (+CDTX) compared to no‐use during active treatment (−CDTX).MethodsData are from 385 surveys collected via REDCap during phase I of an ongoing study among adult cancer patients seen at an NCI‐designated comprehensive cancer center within the last 5 years of treatment. A harmonized survey was created with 11 other NCI centers to assess cannabis use patterns, sources, and reasons for use. Sociodemographics and cancer details were also collected via self‐report. Descriptive statistics were calculated and stratified by +/−CDTX. Chi‐squared tests were conducted to compare proportions between groups.ResultsAmong the sample [49.5 years (SD 15.9); 53.0% male; and 41.6% Hispanic/Latino], 41.0% + CDTX and 59.0% −CDTX. A majority (71.8%) of +CDTX initiated use before diagnosis versus 44.1% in −CDTX (p < 0.0001); patients diagnosed with stage 4 cancer had a statistically significant higher prevalence of +CDTX (60.0%; p = 0.003); 53.3% in radiation reported +CDTX compared to 42.8% in chemotherapy, and 36.4% in immunotherapy. Dispensaries and local dealers were the top sources of cannabis in both groups. Among +CDTX, 44.3% consumed cannabis at least once a day DTX, dominant cannabinoids used were CBD (35.2%), Delta‐8‐THC (18.3%), and CBD + THC ratio (14.1%); 12.7% were unsure what they consumed. Joints were the most common inhalation method (61.5%), and store‐bought candy was the most common edible (39.2%). Depression/mood, pain, and enjoyment were the top three reasons for +CDTX compared to enjoyment, depression/mood, and nausea/upset stomach in −CDTX (p = 0.02).ConclusionsPatterns, sources, and reasons for cannabis use varied between +CDTX and ‐CDTX. Future studies should examine the impacts of cannabis and specific cannabinoids on cancer treatment, drug interactions, survival outcomes, and quality of life.

show abstract

Discussions on Medical Cannabis: Addressing Missed Opportunities in Cancer Education

Luque

2024

J Canc Educ

View full text Add to dashboard Cite

Cannabis use among recently treated cancer patients: perceptions and experiences

Cited by 8 publications

References 41 publications

Review of the Use of Medicinal Cannabis Products in Palliative Care

Review of the Use of Medicinal Cannabis Products in Palliative Care

Cannabis Use Among Cancer Patients During Active Treatment: Findings From a Study at an NCI‐Designated Cancer Center

Discussions on Medical Cannabis: Addressing Missed Opportunities in Cancer Education

Contact Info

Product

Resources

About